10-QPeriod: Q1 FY2002

BIOGEN INC. Quarterly Report for Q1 Ended Mar 31, 2002

Filed May 13, 2002For Securities:BIIB

Summary

IDEC Pharmaceuticals Corporation (now Biogen Inc.) reported a significant increase in revenue for the first quarter of 2002 compared to the same period in 2001, primarily driven by the strong performance of its key drug, Rituxan. Revenues from unconsolidated joint business surged by approximately 34% year-over-year, largely due to higher copromotion profits and increased royalty income from international sales. This revenue growth, coupled with managed operating expenses, led to a substantial increase in net income and earnings per share, indicating improved profitability and operational efficiency. Furthermore, the company highlighted the recent FDA approval of ZEVALIN in February 2002, marking a significant milestone as the first approved radioimmunotherapy. This approval, along with progress in European regulatory submissions for ZEVALIN, positions the company for potential future revenue streams. While the company experienced a decrease in cash and cash equivalents, it also announced a substantial senior convertible debt offering in April 2002, which will strengthen its liquidity and provide capital for future investments and operations. Despite ongoing litigation risks, the overall financial performance shows positive momentum driven by product sales and new product development.

Key Highlights

  • 1Total revenues increased by approximately 41% to $79.7 million for the three months ended March 31, 2002, compared to $56.5 million for the same period in 2001.
  • 2Net income rose significantly by 42.6% to $29.7 million for the first quarter of 2002, up from $20.8 million in the prior year's first quarter.
  • 3Basic earnings per share increased to $0.19 from $0.14, and diluted earnings per share improved to $0.17 from $0.12, demonstrating enhanced profitability on a per-share basis.
  • 4The company received FDA approval for ZEVALIN in February 2002, its first radioimmunotherapy, positioning it for new market opportunities.
  • 5Revenues from unconsolidated joint business, primarily from Rituxan, grew by 33.7% to $78.2 million, driven by increased copromotion profits and international royalties.
  • 6Selling, general, and administrative expenses saw a significant increase of 61.0% to $18.8 million, reflecting investments in marketing and sales for ZEVALIN and Rituxan.
  • 7The company completed a substantial senior convertible debt offering in April 2002, raising approximately $657 million net, bolstering its capital resources for future growth and operations.

Frequently Asked Questions

The primary driver of IDEC Pharmaceuticals' revenue growth is the strong performance of Rituxan, their key drug. Revenues from the unconsolidated joint business, which primarily consist of copromotion profits and royalties from Rituxan sales, increased by approximately 34% year-over-year. This growth was fueled by increased market penetration for Rituxan in treating B-cell non-Hodgkin's lymphoma and initial royalty income from international sales.

The FDA approval of ZEVALIN in February 2002 is a significant milestone as it is the first approved radioimmunotherapy. This approval opens up a new market opportunity for the company, allowing for commercialization in the United States. While the company has retained U.S. marketing and distribution rights, it has granted these rights outside the U.S. to Schering Aktiengesellschaft, indicating a strategy for broader market access. This approval is expected to contribute to future revenue streams, though significant increases in selling, general, and administrative expenses are noted to support its commercialization.

The company's cash and cash equivalents decreased by $44.4 million during the first quarter of 2002, primarily due to significant investments in property and equipment and the purchase of securities available-for-sale. However, the company bolstered its financial position by completing a substantial senior convertible debt offering in April 2002, raising approximately $657 million net of expenses. These proceeds, along with anticipated funds from operations and existing collaborations, are expected to be sufficient to meet operating requirements for the foreseeable future.

Yes, IDEC Pharmaceuticals is involved in significant patent litigation. The company has filed complaints related to ZEVALIN against GlaxoSmithKline and others, seeking declaratory judgments of non-infringement or patent invalidity. Conversely, lawsuits have been filed against IDEC alleging ZEVALIN infringes on existing patents. While the company states it does not believe the ultimate resolution of existing legal matters would have a material adverse effect, these litigations, particularly concerning ZEVALIN and ongoing appeals related to Rituxan, present potential financial and operational risks, including damages, injunctions, or the need for licensing agreements.